TY - JOUR
KW - Adult
KW - agonist treatment
KW - Alcohol
KW - Alcohol-Related Disorders/complications/diagnosis/psychology
KW - Analgesics, Opioid
KW - Behavior, Addictive/diagnosis/therapy
KW - Buprenorphine/therapeutic use
KW - Family Medicine
KW - Female
KW - Focus Groups
KW - Health Services Needs and Demand
KW - Humans
KW - implementation
KW - Male
KW - Mass Screening/methods/organization & administration
KW - Methadone/therapeutic use
KW - Opiate Substitution Treatment/methods
KW - Opioid-Related Disorders/complications/psychology/therapy
KW - Opioids
KW - Oregon
KW - Primary Health Care/methods/standards
KW - Psychological Techniques
KW - Quality Improvement
KW - SBIRT
KW - Substance Abuse Detection/methods
AU - J. Klimas
AU - J. Muench
AU - K. Wiest
AU - R. Croff
AU - T. Rieckman
AU - D. McCarty
A1 - 
AB - Problem alcohol use is associated with adverse health and economic outcomes, especially among people in opioid agonist treatment. Screening, brief intervention, and referral to treatment (SBIRT) are effective in reducing alcohol use; however, issues involved in SBIRT implementation among opioid agonist patients are unknown. To assess identification and treatment of alcohol use disorders, we reviewed clinical records of opioid agonist patients screened for an alcohol use disorder in a primary care clinic (n = 208) and in an opioid treatment program (n = 204) over a two-year period. In the primary care clinic, 193 (93%) buprenorphine patients completed an annual alcohol screening and six (3%) had elevated AUDIT scores. In the opioid treatment program, an alcohol abuse or dependence diagnosis was recorded for 54 (27%) methadone patients. Practitioner focus groups were completed in the primary care (n = 4 physicians) and the opioid treatment program (n = 11 counselors) to assess experience with and attitudes towards screening opioid agonist patients for alcohol use disorders. Focus groups suggested that organizational, structural, provider, patient, and community variables hindered or fostered alcohol screening. Alcohol screening is feasible among opioid agonist patients. Effective implementation, however, requires physician training and systematic changes in workflow.
BT - Journal of psychoactive drugs
C5 - Opioids & Substance Use; Education & Workforce
CP - 1
CY - United States
DO - 10.1080/02791072.2014.991859
IS - 1
JF - Journal of psychoactive drugs
N2 - Problem alcohol use is associated with adverse health and economic outcomes, especially among people in opioid agonist treatment. Screening, brief intervention, and referral to treatment (SBIRT) are effective in reducing alcohol use; however, issues involved in SBIRT implementation among opioid agonist patients are unknown. To assess identification and treatment of alcohol use disorders, we reviewed clinical records of opioid agonist patients screened for an alcohol use disorder in a primary care clinic (n = 208) and in an opioid treatment program (n = 204) over a two-year period. In the primary care clinic, 193 (93%) buprenorphine patients completed an annual alcohol screening and six (3%) had elevated AUDIT scores. In the opioid treatment program, an alcohol abuse or dependence diagnosis was recorded for 54 (27%) methadone patients. Practitioner focus groups were completed in the primary care (n = 4 physicians) and the opioid treatment program (n = 11 counselors) to assess experience with and attitudes towards screening opioid agonist patients for alcohol use disorders. Focus groups suggested that organizational, structural, provider, patient, and community variables hindered or fostered alcohol screening. Alcohol screening is feasible among opioid agonist patients. Effective implementation, however, requires physician training and systematic changes in workflow.
PP - United States
PY - 2015
SN - 0279-1072; 0279-1072
SP - 65
EP - 70
EP - 
T1 - Alcohol Screening among Opioid Agonist Patients in a Primary Care Clinic and an Opioid Treatment Program
T2 - Journal of psychoactive drugs
TI - Alcohol Screening among Opioid Agonist Patients in a Primary Care Clinic and an Opioid Treatment Program
U1 - Opioids & Substance Use; Education & Workforce
U2 - 25715074
U3 - 10.1080/02791072.2014.991859
VL - 47
VO - 0279-1072; 0279-1072
Y1 - 2015
ER -